COVID-19
TOOLBOX
Filter
12
Featured
Language
Document type
Fact sheets
7
Guidelines
3
Studies & Reports
1
Situation Updates
1
Countries / Regions
East and Southern Africa
2
West and Central Africa
2
South Sudan
1
Brazil
1
South Korea
1
Authors & Publishers
World Health Organization WHO
4
Africa CDC Centres for Disease Control and Prevention
3
African Union
3
European Medicines Agency EMA
2
World Health Organization WHO, et al.
2
Greinacher, A., et al.
1
OPAS
1
OPAS, OMS
1
World Health Organization WHO, Regional Office of Europe
1
Publication Years
Category
Countries
4
 External Link
 Add to my

WHO Recommendation AstraZeneca/SKBio - COVID-19 Vaccine (ChAdOx1-S [recombinant])

World Health Organization WHO (2021) C_WHO
 External Link
 Add to my

AstraZeneca’s COVID-19 vaccine: EMA finds possible link to very rare cases of unusual blood clots with low blood platelets

European Medicines Agency EMA (2021) CC
7 April 2021
 Download
  View PDF
 Add to my

Recommandations provisoires concernant l’utilisation du vaccin ChAdOx1-S [‎recombinant]‎ contre la COVID-19 (‎vaccin anti-COVID-19 AZD1222 Vaxzevria™ d’AstraZeneca, COVISHIELD™ de SII)‎
recommended

World Health Organization WHO (2021) C_WHO
orientations provisoires, première publication: 10 février 2021, mise à jour : 21 avril 2021, dernière mise à jour : 30 juillet 2021
 Download
  View PDF
 Add to my

Предварительные рекомендации по применению вакцины ChAdOx1-S [‎рекомбинантной]‎ против COVID-19 (‎вакцина AstraZeneca COVID-19 AZD1222, Vaxzevria™, SII COVISHIELD™)
recommended

World Health Organization WHO (2021) C_WHO
временное руководство. Первый выпуск: 10 февраля 2021 г. Обновлено: 21 апреля 2021 г. Последнее обновление 30 июля 2021г.
 Download
  View PDF
 Add to my

Recomendações provisórias para o uso da vacina ChAdOx1-S [recombinante] contra COVID-19 (vacina AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™) - Última atualização em 30 de julho de 2021

OPAS, OMS OPAS (2021) CC
Interim recommendations for the use of ChAdOx1-S [recombinant] COVID-19 vaccine (AstraZeneca COVID-19 AZD1222 Vaxzevria™, SII COVISHIELD™ vaccine) - Last updated 30 July 2021
 Download
  View PDF
 Add to my

Statement to African Union Member States on the deployment of the AstraZeneca COVID-19 Vaccine to the continent and concerns about adverse event reports coming from Europe

African Union; Africa CDC Centres for Disease Control and Prevention; World Health Organization WHO, et al. (2021) CC
19 March 2021
 External Link
 Add to my

COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events - vaccine’s benefits currently still outweigh risks - Update

European Medicines Agency EMA (2021) CC
11 March 2021
 Download
  View PDF
 Add to my

Africa Regulatory Taskforce has Endorsed the Emergency Used Listing for Two Versions of the AstraZeneca-Oxford Vaccine

African Union; Africa CDC Centres for Disease Control and Prevention; World Health Organization WHO, et al. (2021) C1
AstraZeneca-SKBio in South Korea and Serum Institute of India
 Download
  View PDF
 Add to my

Job aid for COVID-19 vaccine administration: AZD1222 (‎ChAdOx1-S [‎recombinant]‎)‎ COVID-19 vaccine

World Health Organization WHO, Regional Office of Europe (2021) C_WHO
 Download
  View PDF
 Add to my

Déclaration sur l’efficacité du vaccin COVID-19 d’AstraZeneca (ChAdOx1 nCoV-19) contre les variants du SARS-CoV-2
recommended

African Union; Africa CDC Centres for Disease Control and Prevention (2021) C1
On the 9 February 2021, Africa CDC convened a special session of the Africa Task Force for COVID-19 to review existing data and evidence and recommend
 External Link
 Add to my

Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination

Greinacher, A., et al. (2021) CC
New England Journal of Medicine April 9, 2021 DOI: 10.1056/NEJMoa2104840
 External Link
 Add to my

Interim statement of the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety on AstraZeneca COVID-19 vaccine

World Health Organization WHO (2021) C_WHO
7 April 2021 Based on current information, a causal relationship between the vaccine and the occurrence of blood clots with low platelets is considered plausible but is not confirmed. Available in Englisch, French and Russian